MYL : NASDAQ : Health Care
$39.01 up 0.74 | 1.93%
Today's Range: 38.35 - 39.2
Avg. Daily Volume: 5505400.0
06/22/17 - 4:00 PM ET

Financial Analysis


MYLAN NV's gross profit margin for the first quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. MYLAN NV has weak liquidity. Currently, the Quick Ratio is 0.85 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 13.45% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)2719.52191.3
EBITDA ($mil)783.2543.6
EBIT ($mil)367.7246.5
Net Income ($mil)66.413.9


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)981.61306.5
Total Assets ($mil)34272.622644.1
Total Debt ($mil)14959.07474.6
Equity ($mil)11656.010273.4


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin56.1356.49
EBITDA Margin28.7924.8
Operating Margin13.5211.25
Sales Turnover0.340.43
Return on Assets1.553.55
Return on Equity4.567.83
Debt Q1 FY17 Q1 FY16
Current Ratio1.561.67
Debt/Capital0.560.42
Interest Expense128.254.1
Interest Coverage2.874.56


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)535.93491.36
Div / share0.00.0
EPS0.120.03
Book value / share21.7520.91
Institutional Own % n/a n/a
Avg Daily Volume5759732.05296107.0

Valuation


HOLD. The current P/E ratio indicates a significant discount compared to an average of 84.59 for the Pharmaceuticals industry and a significant premium compared to the S&P 500 average of 25.73. To use another comparison, its price-to-book ratio of 1.70 indicates a discount versus the S&P 500 average of 3.08 and a significant discount versus the industry average of 10.76. The price-to-sales ratio is below the S&P 500 average and is well below the industry average, indicating a discount. Upon assessment of these and other key valuation criteria, MYLAN NV proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MYL 36.98 Peers 84.59   MYL 8.21 Peers 19.60

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

MYL is trading at a significant discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MYL is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
MYL 6.48 Peers 16.00   MYL 0.08 Peers 0.70

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

MYL is trading at a significant discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

MYL trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MYL 1.70 Peers 10.76   MYL -35.90 Peers 19.71

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MYL is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, MYL is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MYL 1.71 Peers 11.00   MYL 19.04 Peers 5.56

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MYL is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

MYL has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades